<DOC>
	<DOCNO>NCT01883661</DOCNO>
	<brief_summary>The aim study prove BMMNC Therapy Multiple sclerosis , control symptom help maintain normal quality life suffer patient .</brief_summary>
	<brief_title>Safety Efficacy BMMNC Multiple Sclerosis ( MS )</brief_title>
	<detailed_description>Multiple sclerosis ( MS ) consider autoimmune disease cause immune system attack central nervous system ( CNS ) lead myelin loss axonal damage , result long-term disability . The pathophysiology MS complex involvement genetic environmental factor define susceptibility generate autoimmune attack . MS cause damage myelin sheath , protective cover surround nerve cell . When nerve cover damage , nerve signal slow stop.The nerve damage cause inflammation . Inflammation occur body 's immune cell attack nervous system . Currently , treatment MS relay mainly immunosuppression combine monoclonal antibody steroid therapies.The advanced application MSCs neurological clinical arena multiple sclerosis.This clinical study time period 1 year . This study carry see role BMMNC cell Therapy Multiple sclerosis , control symptom help maintain normal quality life suffer patient .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Confirmed Diagnosis MS , Aged 18 65 year . Duration disease : &gt; 5 year Signed , write informed consent Willing able comply study visit accord protocol full study period Patients suffer significant cardiac , renal hepatic failure disease may risk patient interfere ability interpret result Patient active chronic infection No lifethreatening organ dysfunction . Pregnancy risk pregnancy . Patients seropositive HIV1 , HIV2 , Hepatitis B Surface Antigen , Hepatitis C Patients unable give write informed consent accordance research ethic board guideline Treatment immunosuppressive therapy , include natalizumab fingolimod , within 3 month prior randomization Treatment interferonbeta glatiramer acetate within 30 day prior randomization Treatment corticosteroid within 30 day prior randomization Current treatment investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>stem cell</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>BMMNC</keyword>
</DOC>